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CASE REPORT
Pruritus, a rare but troublesome adverse reaction
of topiramate
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Case series report of presence of pruritus in five patients taking topiramate for treatment of epilepsy. This is a benign side effect
of topiramate not previously reported that interfered with seizure treatment. Four out of five patients have previous history of
antiepileptic drug (AED) allergy. Only one patient improved with a very slow titration, three of them discontinued treatment
and one remained on a sub-therapeutic dose.
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INTRODUCTION
Topiramate is a sulfamate-substituted monosaccharide
that is intended for use as an antiepileptic drug (AED).
Topiramate also inhibits some isoenzymes of carbonic
anhydrase (CA-II and CA-IV). This pharmacologic
effect is generally weaker than that of acetazolamide,
a known carbonic anhydrase inhibitor3–5. Paresthe-
sia, an effect associated with the use of other car-
bonic anhydrase inhibitors, appears to be a common
effect of topiramate3. Rash occurred in more than 1%
of adults treated with 200–400 mg of topiramate in
placebo-controlled trials but with equal or greater fre-
quency in the placebo group5. There are no previous
reports of pruritus with use of topiramate.
MATERIALS AND METHODS
A retrospective case review of five patients with
epilepsy who experienced pruritus after addition of
topiramate to their anticonvulsant treatment.
History of previous allergies, concomitant medi-
cations, titration rate, and therapeutic strategies to
control the side effects were analysed.
CASE #1
H.O. is a 47-year-old man with heterotopia and
squizencephaly in the left parieto-occipital region
and remote symptomatic seizures, refractory to
medications.
Seizure onset: 4 years of age (with and without fever).
Seizure type: Complex partial with occasional sec-
ondary generalisation. Aura of weird feeling.
Seizure frequency: Daily complex partial seizures,
once a month secondary generalisation.
EEG: T5 spikes, frequent. Focal slowing left poste-
rior head region.
Past history: Otherwise unremarkable.
Previous allergies: Lamotrigine (benign rash).
Previous AEDs: Phenobarbitone, lamotrigine, val-
proic acid.
Concomitant drugs: Phenytoin 400 mg/day, gaba-
pentin 2700 mg/day.
Topiramate dose: 25 mg/day. Increment to 50 mg/day
2 weeks later resulted in diffuse body itching with-
out visible rash. Symptom reversed after lowering
dose again to 25 mg/day.
Outcome: Topiramate was discontinued.
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CASE #2
S.S. is a 32-year-old woman with a history of idio-
pathic epilepsy refractory to treatment mainly due to
medication intolerance.
Seizure onset: 15 years of age.
Seizure type: Generalised tonic–clonic, mainly noc-
turnal. Rare diurnal seizures without aura.
Seizure frequency: 1–2 year.
EEG: Generalised, bifrontal predominant, polyspike
and wave bursts of 3.5–4.5 Hz.
Past history: Depression, hypothyroidism.
Previous allergies: Lamotrigine (benign rash associ-
ated with higher than 50 mg/day dose), iodine.
Previous AEDS: Phenobarbitone, lamotrigine.
Concomitant drugs: AEDs—valproic acid 750 mg/
day, unable to tolerate a higher dose, and phenytoin
350 mg/day. Other drugs include lithium, sertraline
and levothyroxine.
Topiramate dose: 25 mg/day. Increment 25 mg/day
every 2 weeks. Itching developed at 125 mg/day.
Dose reduced to 100 mg/day improved symptom.
Further slow titration up to 250 mg/day again
induced itching. Dose reduction to 200 mg/day
improved pruritus. No visible rash reported. The
patient reported itching associated with high tem-
peratures at this dose.
Outcome: Partial improvement in seizure frequency.
No significant side effects reported at 200 mg/day
of topiramate.
CASE #3
O.C. is a 23-year-old woman with juvenile myoclonic
epilepsy, refractory to medical treatment.
Seizure onset: 11 years of age.
Seizure type: Generalised tonic–clonic and my-
oclonic.
Seizure frequency: Daily myoclonus (early morn-
ing), GTC once a month.
EEG: None recent. Result not available.
Past history: Otherwise unremarkable.
Previous allergies: Phenobarbitone (rash), lamotrig-
ine (benign rash with high dose only).
Previous AEDs: Phenobarbitone, lamotrigine, val-
proic acid (GI intolerance), carbamazepine (in-
creased myoclonus).
Concomitant drugs: Phenytoin 600 mg/day, clon-
azepam 4 mg/day.
Topiramate dose: 25 mg/day. Increment to 50 mg/day
2 weeks later resulted in diffuse body itching with-
out visible rash. Symptom reversed after lowering
dose again to 25 mg/day.
Outcome: Topiramate was discontinued.
CASE #4
D.L. is a 66-year-old woman with frontal lobe epilepsy
refractory to medical treatment.
Seizure onset: 5 years of age.
Seizure type: Generalised tonic–clonic.
Seizure frequency: GTC once a month, daily staring
episodes.
EEG: Right frontal spikes with frequent secondary
bilateral synchrony.
Past history: Head trauma at age 5 years (scalp lac-
eration, unclear loss of consciousness).
Previous allergies: Phenytoin (rash), valproic acid
(pruritus), lamotrigine (pruritus with dose above
150 mg/day).
Previous AEDs: Phenobarbitone, lamotrigine, val-
proic acid.
Concomitant drugs: Carbamazepine 1400 mg/day.
Topiramate dose: 25 mg/day. Increment to 50 mg/day
1 week later resulted in diffuse body itching without
visible rash, the symptom improved after 1 week,
slow titration up to 25 mg/day every other week was
well tolerated.
Outcome: Topiramate was titrated up to 300 mg/day.
Seizures were controlled at this dose without sig-
nificant side effects.
CASE #5
B.I. is a 42-year-old woman with refractory temporal
lobe epilepsy.
Seizure onset: Febrile convulsion at age 8 months
old, subsequent afebrile seizures ever since.
Seizure type: Complex partial with bilateral temporal
onset as recorded on video-EEG monitoring.
Seizure frequency: Two to three complex partial
seizures a week.
EEG: Independent spikes in the left and right tem-
poral regions.
Past history: Respiratory distress, seizure and high
fever (104 ◦F) at age 8 months otherwise normal.
Previous allergies: None.
Concomitant drugs: Valproic acid and lamotrigine.
Topiramate dosing schedule: Initial titration by
25 mg every week up to 300 mg twice daily was
well tolerated and produce partial improvement
of seizure frequency. Further titration by 25 mg
every week up to 700 mg a day was associated
with intense pruritus without visible skin rash.
Tapered down to 400 mg a day resolved the
symptoms.
Outcome: Partial seizure frequency reduction with
a maximum dose tolerated 400 mg a day due to
pruritus at higher doses.
518 J. G. Ochoa
Fig. 1: Allergy history and outcome.
DISCUSSION
Paresthesia has been reported with the use of topira-
mate but to my knowledge pruritus has never been re-
ported. Anticonvulsant hypersensitivity syndrome has
not been described in patients taking benzodiazepines,
gabapentin or topiramate1. The history of allergic
reaction to other anticonvulsants in most of these
patients favours that this symptom may be related to
allergy rather than carbonic anhydrase inhibition ex-
cept for one patient who reported increase in pruritus
with higher ambient temperature which may be re-
lated to inhibition of CA-II enzyme that may cause
increase of heat storage during exercise and decrease
in whole-body sweat loss2. In this particular case, the
pruritus may be also triggered by skin dryness (Fig. 1).
Although topiramate is a sulfamate compound, none
of these patients had history of hypersensitivity to
sulfa drugs and it is not clear whether this reaction
may be related to sulfa allergy. Interestingly, I found
no reports of use of topiramate in patients with hyper-
sensitivity to sulfa drugs.
Pruritus appears to be a benign allergic reaction that
occurs rarely in patients taking topiramate and causes
either a sub-therapeutic dose or drug discontinuation.
It does not appear to be caused by concomitant med-
ication and it is not clearly related to any particular
concomitant drug. Slow titration helped in one case
only.
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